BLLN · BillionToOne, Inc.

The thesis

BillionToOne's prenatal and cancer testing business is growing 64% a year and is profitable, and the shares have bounced back to $111.47 (close, 26 October 2026) from $94.44 on 13 October 2026. The third-quarter report on 4 November 2026, after the market close, decides whether revenue and margin justify the rebound. Until it arrives the shares look about as likely to lag the S&P 500 as to lead it, so the rating stays at the low end.

The price is 25.7% below the $149.97 52-week high and down 15.9% over three months, per adjusted daily closes. The 14-day relative strength index is 64.5, up from 32 on 13 October 2026. The close sits above the 50-day moving average of $106.67 and the 200-day of $100.31 that MarketBeat reported on 6 October 2026. Both averages have moved since then, so the exact gap is not known.

The business record has not changed since the second-quarter report of 5 August 2026: revenue of $109.4 million, up 64% year over year, operating income of $5.5 million, and full-year revenue guidance of $450–465 million. The narrative is maturing: coverage is wide, with Guggenheim lifting its target to $128 on 1 October 2026, and the 14 October 2026 announcement of the report date is the only company event since the last note.

Bullish and bearish views on BillionToOne, Inc.

The bull case on BillionToOne, Inc. (BLLN), in brief: Revenue is growing with test volume. The bear case: The recovery is recent and unconfirmed by results.

Bull case

• Revenue is growing with test volume. The 5 August 2026 report showed 196,000 second-quarter tests delivered, up 35% year over year, and revenue up 64% to $109.4 million. Operating income of $5.5 million means the growth is profitable.
• Oncology is small but compounding fast. Second-quarter oncology revenue was $13.7 million, up 176% year over year, per the company's results release. On 7 October 2026 the company reported a peer-reviewed study in which its tissue-free Northstar Response test matched a tumor-informed circulating tumor DNA test on tumor-burden direction in 67 of 71 sequential pairs (94%).
• Analyst targets sit well above the price. MarketBeat listed a consensus target of $126.25 on 6 October 2026, from 7 Buy, 3 Hold and 1 Sell ratings. Guggenheim's target is $128 (1 October 2026), Canaccord Genuity initiated at Buy with a $120 target (2 September 2026), and JPMorgan and BTIG both sit at $130 (6 August 2026).
• Medicare repricing was reported as favourable. Benzinga reported on 23 September 2026 that the preliminary 2027 Centers for Medicare & Medicaid Services (CMS) clinical lab fee update brought positive changes for BillionToOne tests. The dollar effect has not been quantified.

Bear case

• The recovery is recent and unconfirmed by results. The shares closed at $94.44 on 13 October 2026 and $111.47 on 26 October 2026, with no new financial results in between. The next filed numbers arrive on 4 November 2026.
• Insider supply continues. CTO David Tsao sold 20,000 shares on 5 October 2026 at a weighted average of $108.39 under a Rule 10b5-1 plan adopted 5 June 2026, per his Form 4. A Form 4 for SVP John Roderick ten Bosch shows sales on 5 October 2026 at $105.15, and company news on 19 October 2026 reported further insider sales. MarketBeat counted 216,357 shares, about $24.6 million, sold by insiders over the 90 days to 6 October 2026.
• The valuation leaves little room for a miss. At the $98.09 close on 9 October 2026 the market value was $4.63 billion, about 11.3 times sales, per Gotrade. At the higher $111.47 close the multiple is larger. A 5% operating margin in the second quarter gives little room for higher spending or a revenue shortfall.
• The September–October drop had no identified cause. No company news explained the declines of 30 September 2026 and 6 October 2026, and a move with no stated cause can reverse as quickly as the rebound did.

Price setup

The adjusted daily closes show a fall from the $149.97 52-week high to $94.44 on 13 October 2026, then a rise to $111.47 on 26 October 2026. The shares have a short trading history since the late-2025 Nasdaq listing, so the 200-day average and the 52-week range cover less than two years.

The prior $100–110 area, where insiders sold on 5 October 2026, is the zone the shares are now trading through. The 13 October 2026 close of $94.44 is the recent low. The invalidation level at $81.84 is the start-of-year close.

Crowding evidence is limited to three observable items: an earnings report nine days away, recurring insider sales under 10b5-1 plans, and a relative strength reading of 64.5 after a sharp two-week rise.

Catalysts, next 30 days

• The report tests the $450–465 million full-year revenue guidance, oncology growth and the thin operating margin.
• Through November, dates not set: Further Form 4 filings from executives selling under 10b5-1 plans.
• Later, date not announced: Final CMS 2027 clinical lab fee rates, which would settle whether the preliminary changes benefit BillionToOne's revenue.

What would change the view

The operating case breaks if the third-quarter report cuts full-year revenue guidance below the $450 million floor, or shows an operating loss after the $5.5 million operating profit of the second quarter. Slower oncology growth than the 176% of the second quarter would weaken the main growth argument.

The price case breaks on a daily close below $81.84, the start-of-year level. A final CMS fee schedule that reverses the preliminary changes would remove one of the supports of the bull case. A strong report, with revenue growth near 64% and a profitable quarter, would show results confirming the rebound and would move the rating up.

What it trades with

BillionToOne trades with other recently listed growth diagnostics and genomic testing companies, and with small- and mid-cap healthcare shares more broadly. CareDx was named alongside it in the Benzinga report of 23 September 2026 on Medicare lab fees, so lab-payment news can move both. The shares have no current theme cluster that explains the September–October swings.